GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » Debt-to-Asset

Rhythm Pharmaceuticals (FRA:1RV) Debt-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Debt-to-Asset?

Rhythm Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.73 Mil. Rhythm Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.26 Mil. Rhythm Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €237.96 Mil. Rhythm Pharmaceuticals's debt to asset for the quarter that ended in Mar. 2024 was 0.00.


Rhythm Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Rhythm Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Debt-to-Asset Chart

Rhythm Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.01 0.02 0.01 0.01 -

Rhythm Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - - -

Competitive Comparison of Rhythm Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Debt-to-Asset falls into.



Rhythm Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rhythm Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.706 + 0.449) / 305.127
=0.00

Rhythm Pharmaceuticals's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Pharmaceuticals  (FRA:1RV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Rhythm Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Pharmaceuticals (FRA:1RV) Business Description

Traded in Other Exchanges
Address
222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Rhythm Pharmaceuticals (FRA:1RV) Headlines

No Headlines